Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates. Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium. For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register. For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.
Patent details
2661278
Title:
ANTICORPS CYTOTOXICITÉ DÉPENDANTE DU COMPLÉMENT (CDC) SPÉCIFIQUE D'UNE TUMEUR GÉNÉRÉE PAR L'ADMINISTRATION DU VACCINIA VIRUS ONCOLYTIQUE, POUR LE TRAITEMENT DU CANCER
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic information
Application number:
127322634
WO application number:
US2012020173
Type:
European patent granted for BE
Status:
Lapsed
Publication number:
2661278
WO publication number:
WO2012094386
1rst applicant's nationality:
Translation language:
EPO publication language:
English
SPC number:
Dates
Filing date:
04/01/2012
Grant date:
19/06/2019
EP publication date:
13/11/2013
WO publication date:
12/07/2012
Claims translation received date:
Translation received date (EP publication B1):
Translation received date (EP publication B2):
Translation received date (EP publication B3):
Registration date:
19/06/2019
EP B1 publication date:
19/06/2019
EP B2 publication date:
EP B3 publication date:
Lapsed date:
31/01/2020
Expiration date (if granted and all annual fees paid):
04/01/2032
Applicant
1
Name:
SillaJen Biotherapeutics, Inc.
Legal Form:
From:
19/06/2019
Address:
450 Sansome Street, Suite 650, San Francisco, CA 94111, United States (US)
To:
2
Name:
Sillajen, Inc.
Legal Form:
From:
19/06/2019
Address:
307 Hyowon IC Building
Pusan National University San 30, Busan 609-735, Korea (Republic) (KR)
To:
Inventor
1
Name:
KIRN, David
Legal Form:
Address:
Mill Valley
California 94941, United States (US)
2
Name:
BELL, John
Legal Form:
Address:
Ottawa
Ontario K1H 8L6, Canada (CA)
3
Name:
BREITBACH, Caroline
Legal Form:
Address:
San Francisco
California 94109, United States (US)
4
Name:
MOON, Anne
Legal Form:
Address:
San Francisco
California 94111, United States (US)